Opinion|Videos|July 29, 2024
Ongoing Research in Hidradenitis Suppurativa
Author(s)Vivian Shi, MD, FAAD
An expert on hidradenitis suppurativa gives an overview of the current research landscape, highlighting exciting developments in the treatment space.
Advertisement
Episodes in this series
Video content above is prompted by the following question:
- What are the other investigational agents for hidradenitis suppurativa (HS) that you are excited about and what is their stage in development?
Advertisement
Related to this article
FDA granted accelerated approval to dostarlimab-gxly for dMMR or MSI-H locally advanced rectal cancer based on interim phase 2 AZUR-1 results.
Phentolamine 0.75% (Ryzumvi) won FDA approval for presbyopia based on the phase 3 VEGA-2 and VEGA-3 trials.
Nearly 3 in 4 bariatric surgery candidates had clinical obesity, a phenotype that BMI alone did not distinguish from preclinical obesity.
Satralizumab, a first-in-class IL-6 receptor inhibitor, was approved for adults with thyroid eye disease based on the phase 3 SatraGO program.
A review of 47 endometriosis guidelines found most came from high-income settings and diverged on biomarkers, repeat surgery, and fertility referral.
The meeting covered several topics in eye care, including how artificial intelligence (AI) can play a part in eye care.
A meta-analysis of 27 trials found a 15% cardiovascular risk reduction per 10-mm Hg lower systolic BP, with no added risk of kidney failure.
In a Japanese registry of 1235 patients with AMI treated with PCI, Lp(a) of 24 mg/dL or higher independently predicted MACE and HF hospitalization.
Advertisement
Advertisement
Trending on AJMC
1
Pathological Response Does Not Reliably Predict Survival in Sarcoma
2
New CHEST Guidelines Offer a Road Map for Bronchiectasis
3
CHEST Investigations Explore COPD Guideline Adherence, Adding Ensifentrine, and Use of AI in Education
4
CHEST Highlights Practice-Changing COPD Therapy and Strategies
5